Cushing Disease Clinical Trial
Official title:
The Factors Associated With the Recurrence in Patients With Cushing Disease
Cushing syndrome refers the manifestations induced by chronic glucocorticoid excess and may
arise from various causes. Iatrogenic Cushing syndrome accounts for most patients, when they
are given exogenous glucocorticoid treatment. In contrast, spontaneous Cushing syndrome
results from endogenous glucocorticoid over-secretion. Although Cushing disease is rare, it
is the most common cause of spontaneous Cushing syndrome. The patient with Cushing disease
has a pituitary corticotroph adenoma, which overproduces adrenocorticotropic hormone (ACTH).
ACTH then stimulates adrenal gland to over-secret glucocorticoid. Patients with untreated
Cushing disease were shown to have poor prognosis, estimated a 5-year survival rate of 50%.
The first line treatment is tumor resection. Other managements include radiotherapy,
medication and bilateral adrenalectomy. The initial remission rate is high (66-90%).
However, some patients encounter with disease recurrence during follow-up.
The aim of this study is to clarify the factors associated with the recurrence after
treatment. In this study, we will review the patients with Cushing disease thoroughly and
analyze associated predisposing factors. These risk factors can remind the clinical
physician to early detect the recurrent disease in these patients, and further prevent
morbidity and mortality in their later lives.
n/a
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02350153 -
Cushing´s Disease Epidemiology in Sweden
|
||
| Not yet recruiting |
NCT03297892 -
Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015
|
N/A | |
| Recruiting |
NCT05804669 -
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Recruiting |
NCT03774446 -
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
|
Phase 2 | |
| Completed |
NCT03080181 -
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
|
Phase 4 | |
| Recruiting |
NCT03831958 -
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
|
||
| Completed |
NCT01331239 -
Safety and Efficacy of LCI699 in Cushing's Disease Patients
|
Phase 2 | |
| Completed |
NCT04201444 -
Hair Cortisol and Cushing's Disease
|
N/A | |
| Recruiting |
NCT04374721 -
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
|
N/A | |
| Recruiting |
NCT03974789 -
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
|
||
| Completed |
NCT03621280 -
Open-label Treatment in Cushing's Syndrome
|
Phase 3 | |
| Not yet recruiting |
NCT05971758 -
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
|
Phase 2 | |
| Recruiting |
NCT04486859 -
Postoperative Thrombosis Prevention in Patients With CD
|
N/A | |
| Completed |
NCT00171951 -
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
|
Phase 2 | |
| Recruiting |
NCT00001595 -
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
|